Ascierto PA - Search Results

1

The role of BRAF V600 mutation in melanoma.

Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. Ascierto PA, et al. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. J Transl Med. 2012. PMID: 22554099 Free PMC article.

2

Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma.

Ascierto PA, Satriano RA, Palmieri G, Parasole R, Bosco L, Castello G. Ascierto PA, et al. Melanoma Res. 1998 Dec;8(6):529-37. doi: 10.1097/00008390-199812000-00008. Melanoma Res. 1998. PMID: 9918415

3

Adjuvant therapy of cutaneous melanoma.

Ascierto PA, Palmieri G. Ascierto PA, et al. Lancet. 1999 Jan 23;353(9149):328. doi: 10.1016/s0140-6736(05)74894-7. Lancet. 1999. PMID: 9929057 No abstract available.

4

3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma.

Ascierto PA, Palmieri G, Parasole R, Daponte A, Castello G. Ascierto PA, et al. Int J Mol Med. 1999 Mar;3(3):303-6. doi: 10.3892/ijmm.3.3.303. Int J Mol Med. 1999. PMID: 10028056 Clinical Trial.

5

Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.

Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Palmieri G, et al. Among authors: ascierto pa. J Clin Oncol. 1999 Jan;17(1):304-11. doi: 10.1200/JCO.1999.17.1.304. J Clin Oncol. 1999. PMID: 10458247

6

Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study.

Ascierto PA, Palmieri G, Celentano E, Parasole R, Caracò C, Daponte A, Chiofalo MG, Melucci MT, Mozzillo N, Satriano RA, Castello G. Ascierto PA, et al. Br J Dermatol. 2000 May;142(5):893-8. doi: 10.1046/j.1365-2133.2000.03468.x. Br J Dermatol. 2000. PMID: 10809845

7

Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group.

Ascierto PA, Palmieri G, Strazzullo M, Daponte A, Botti G, Satriano SM, Motti ML, Mozzillo N. Ascierto PA, et al. Ann Oncol. 2000 Apr;11(4):487-90. doi: 10.1023/a:1008375418507. Ann Oncol. 2000. PMID: 10847472 Free article. No abstract available.

8

Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.

Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G. Ascierto PA, et al. Cancer. 2000 Oct 1;89(7):1490-4. doi: 10.1002/1097-0142(20001001)89:7<1490::aid-cncr11>3.0.co;2-v. Cancer. 2000. PMID: 11013362 Clinical Trial.

9

Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group.

Palmieri G, Pirastu M, Strazzullo M, Ascierto PA, Satriano SM, Motti ML, Botti G, Mozzillo N, Castello G, Cossu A, Lissia A, Tanda F. Palmieri G, et al. Among authors: ascierto pa. Recent Results Cancer Res. 2001;158:200-3. doi: 10.1007/978-3-642-59537-0_20. Recent Results Cancer Res. 2001. PMID: 11092047

10

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.

Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G; Italian Cooperative Oncology Group. Daponte A, et al. Among authors: ascierto pa. Cancer. 2000 Dec 15;89(12):2630-6. Cancer. 2000. PMID: 11135225 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

684 results

Search Page